Datopotamab deruxtecan: observed
3 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- TROPION Breast Respond in 1L TNBCNot yet recruitingNCT07867470Report a problem
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic ResponseRecruitingNCT07582887Report a problem
- Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC PatientsApproved for marketingNCT06279728Report a problem